AbbVie Inc. Linzess/Constella revenue
Linzess/Constella revenue at AbbVie Inc. came to $175.0M for the quarter to 31 Dec 2025, down 24.9% from a year earlier.
As AbbVie Inc. reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 4 Feb 2026.
By quarter
| Period ending | Linzess/Constella revenue | Change on a year | Filed |
|---|---|---|---|
| 31 Dec 2025 | $175.0M | down 24.9% | 4 Feb 2026 |
| 30 Sep 2025 | $326.0M | up 39.3% | 31 Oct 2025 |
| 30 Jun 2025 | $258.0M | up 16.7% | 31 Jul 2025 |
| 31 Mar 2025 | $148.0M | down 44.4% | 25 Apr 2025 |
| 31 Dec 2024 | $233.0M | down 17.7% | 31 Jan 2025 |
| 30 Sep 2024 | $234.0M | down 18.8% | 30 Oct 2024 |
| 30 Jun 2024 | $221.0M | down 20.5% | 25 Jul 2024 |
| 31 Mar 2024 | $266.0M | up 2.7% | 26 Apr 2024 |
| 31 Dec 2023 | $283.0M | up 5.2% | 2 Feb 2024 |
| 30 Sep 2023 | $288.0M | — | 27 Oct 2023 |
| 30 Jun 2023 | $278.0M | — | 27 Jul 2023 |
| 31 Mar 2023 | $259.0M | — | 27 Apr 2023 |
| 31 Dec 2022 | $269.0M | — | 9 Feb 2023 |
Definition
Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.
Other operating KPIs of AbbVie Inc.: Skyrizi revenue · Rinvoq revenue · Botox Therapeutic revenue · Vraylar revenue · Venclexta revenue · Humira revenue · Botox Cosmetic revenue · Imbruvica revenue · Ubrelvy revenue · Qulipta revenue · Creon revenue · Vyalev revenue · Mavyret revenue · Elahere revenue · Juvederm Collection revenue · Ozurdex revenue · Epkinly revenue · Lumigan/Ganfort revenue · Duodopa revenue · Alphagan/Combigan revenue · Immunology revenue · Neuroscience revenue · Oncology revenue · Aesthetics revenue · financial statements
Every KPI and segment of ABBV, in the terminal.
Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.
